Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingWellCare Genetic Testing Coverage Update | OpenPay…
    Ask Trek AI about this page
    ModifiedWellCarePolicy 1

    Concert Genetics Genetic Testing: Aortopathies and Connective Tissue Disorders V1.2024

    Customize your policy alerts

    Sign up for WellCare Policy 1 alerts

    Get alerted when Policy 1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity criteria and coding for genetic testing (single-gene, targeted familial variant, and multigene panels) used to diagnose or confirm hereditary aortopathies and connective tissue disorders for WellCare members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerWellCare
    PolicyConcert Genetics Genetic Testing: Aortopathies and Connective Tissue Disorders V1.2024
    Policy CodePolicy Policy 1
    Change TypeOperational editsremoval and addition of panel references
    Effective DateOct 1, 2023
    Last ReviewOct 1, 2023
    Next Review DateOct 1, 2023
    Key ActionDocument clinical criteria and family history in the record and verify appropriate CPT code and registered test on the Concert Genetics platform before submitting authorization or claims.
    SourceLink
    POLICY UPDATE CHANGES

    Updated title to reflect V1.2024 version and replaced 'coverage criteria' terminology with 'criteria' throughout the policy.

    Removed references to 'Comprehensive Ehlers-Danlos Syndrome Multigene Panels' in the vEDS section and related panel coding numbers.

    Added statement referencing GeneReviews content (e.g., FBN1-Related Marfan Syndrome) and updated gene lists to include genes associated with heritable thoracic aortic disease (HTAD).

    Policy V1.2024Document version
    81403Targeted familial variant code
    81410/81411Comprehensive panel codes
    COL3A1vEDS primary gene
    Z>2.0Aortic Z-score threshold
    PresentInvestigational statements

    Coverage Criteria

    Known Familial Variant Analysis

    Targeted familial variant analysis (81403) is covered when ALL of the following are met:

    Known familial variant required: The member/enrollee has a close relative with a known pathogenic or likely pathogenic variant causing the condition.

    Targeted mutation analysis (81403) is considered investigational for all other indications.

    Comprehensive Connective Tissue Disorders Multigene Panel

    Comprehensive connective tissue disorders multigene panel analysis (81410, 81411) is considered medically necessary when the member meets at least one of the specified disorder criteria:

    Indication list: Member meets criteria for at least one specified disorder such as Classic Ehlers-Danlos Syndrome (cEDS) or Vascular Ehlers-Danlos Syndrome (vEDS).

    Comprehensive multigene panels are considered investigational for isolated hypermobility and hypermobile Ehlers-Danlos syndrome (hEDS) and for other indications not meeting criteria.

    Marfan syndrome - FBN1 testing

    FBN1 sequencing and/or deletion/duplication analysis (81408, 81479) is covered to confirm Marfan syndrome when ALL of the following are met:

    Marfan testing criteria: Member has aortic root enlargement (Z-score ≥ 2) or dissection AND either ectopia lentis OR sufficient systemic features totaling a systemic score ≥7 using the listed point system.Aortic root Z-score ≥2; Systemic score ≥7

    If a panel is performed, FBN1 should be included or prior FBN1 testing must be negative; FBN1 testing is investigational for other indications.

    Loeys-Dietz Syndrome Multigene Panel

    Loeys-Dietz syndrome multigene panel analysis (81405, 81408, 81479) is considered medically necessary when the member meets the following:

    LDS clinical criteria: Member meets at least two characteristic clinical features (for example: characteristic facial features including widely spaced eyes/craniosynostosis; bifid uvula/cleft palate; arterial tortuosity; aortic dilatation or dissection; joint hypermobility), OR has a first-degree relative with clinical LDS as specified.>=2 features

    Panel must include at minimum SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, and TGFBR2. If both aortic root enlargement and ectopia lentis are present, FBN1 should be included or previously tested with negative results.

    COVERAGE CRITERIA — FBN1 sequencing/deletion-duplication for Marfan

    FBN1 sequencing and/or deletion/duplication analysis to confirm Marfan syndrome is medically necessary when ALL of the following are present:

    Marfan testing necessity

    • Primary aortic finding: Aortic root enlargement (Z-score ≥2) OR aortic dissection
    • Secondary criteria: Ectopia lentis OR systemic features totaling ≥7 points per listed scoring items

    LDS panel medical necessity

    Loeys-Dietz syndrome (LDS) multigene panel is medically necessary when the following are met:

    LDS criteria: Member meets at least two listed clinical features (see policy for full listing) OR has a relevant family history as described; the panel must include at minimum SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, and TGFBR2.>=2 features

    LDS testing is investigational for other indications.

    TAAD panel medical necessity

    Familial thoracic aortic aneurysm and dissection (TAAD) multigene panel is medically necessary when ALL of the following are met:

    TAAD panel necessity: Member has aortic root enlargement or history of thoracic aneurysm or aortic dissection, AND does not meet diagnostic criteria for another connective tissue disorder, AND there is a family history of aortic root dilation/dissection consistent with autosomal dominant inheritance, AND the panel includes at minimum ACTA2, FBN1, MYH11, TGFBR1, and TGFBR2.

    cEDS panel medical necessity

    Classic Ehlers-Danlos syndrome (cEDS) multigene panel (limited to COL5A1, COL5A2, COL1A1) is medically necessary when ALL of the following are met:

    cEDS panel necessity: Member has skin hyperextensibility and atrophic scarring, AND either generalized joint hypermobility OR at least three listed additional features (easy bruising; soft, doughy skin; skin fragility; molluscoid pseudotumors; subcutaneous spheroids; hernia; epicanthal folds; complications of joint hypermobility; family history of a first-degree relative with cEDS).

    Panel must be limited to COL5A1, COL5A2, COL1A1. cEDS is most often caused by COL5A1/COL5A2 variants (>90%).

    vEDS COL3A1 testing

    COL3A1 sequencing and/or deletion/duplication analysis for vEDS (81479) is medically necessary when ANY of the following are present:

    vEDS indications: Arterial rupture/dissection under age 40; spontaneous sigmoid colon perforation without known diverticular disease; uterine rupture in third trimester without prior C-section; carotid–cavernous sinus fistula without trauma; a close relative with clinical vEDS or documented COL3A1 variant; OR at least two minor criteria (bruising, thin translucent skin, characteristic facies, spontaneous pneumothorax, acrogeria, talipes equinovarus, congenital hip dislocation, small-joint hypermobility, tendon/muscle rupture, keratoconus, gingival recession/fragility, early-onset varicose veins).

    Other connective tissue disorders

    Genetic testing for other rare connective tissue disorders is medically necessary when ALL of the following are met:

    Other disorders: Member demonstrates clinical features consistent with the specific rare connective tissue disorder listed (examples include arthrochalasia EDS, brittle cornea syndrome, cardiac-valvular EDS, classical-like EDS, dermatosparaxis EDS, kyphoscoliotic EDS, musculocontractural EDS, myopathic EDS, periodontal EDS, spondylodysplastic EDS) and testing targets the associated gene(s).

    FBN1 / Marfan syndrome

    Molecular testing (single-gene or panel) is indicated when clinical diagnostic criteria are met or when clinical findings are equivocal and testing can clarify diagnosis:

    Marfan-related testing indications: Genetic testing of FBN1 is appropriate in probands with aortic root enlargement (Z-score >2.0) plus ectopia lentis, or aortic root enlargement plus multiple systemic features, and is useful in equivocal cases where clinical criteria are insufficient.Aortic root Z-score >2.0

    ACMG and GeneReviews guidance cited.

    Loeys-Dietz syndrome / LDS panels

    Testing for Loeys-Dietz spectrum disorders is indicated when molecular confirmation will establish the diagnosis:

    LDS diagnostic confirmation: Diagnosis is established in a proband with a heterozygous pathogenic or likely pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 AND either aortic root enlargement (Z-score >2.0) or compatible systemic features (including arterial tortuosity); in some nosologies, mutation in TGFBR1/TGFBR2/SMAD3/TGFB2 with documented aneurysm/dissection is sufficient.Z-score >2.0

    GeneReviews and MacCarrick et al cited.

    HTAD multigene panels

    Heritable thoracic aortic disease (HTAD) multigene panel testing is recommended when clinical findings, family history, or imaging suggest an inherited aortopathy:

    HTAD multigene panel: A multigene panel that includes HTAD-associated genes (for example: ACTA2, COL3A1, FBN1, MYH11, MYLK, SMAD3, TGFB2, TGFBR1, TGFBR2, LOX, PRKG1, and others listed in GeneReviews) is recommended when phenotype, family history, or imaging (e.g., aortic root Z-score >2.0, arterial tortuosity, early arterial rupture) indicate heritable thoracic aortic disease.

    GeneReviews recommends panels; ACCF supports family cascade testing.

    Ehlers-Danlos syndromes (cEDS and vEDS)

    Ehlers-Danlos syndromes testing criteria (cEDS and vEDS):

    Classical EDS (cEDS): Testing is indicated when clinical criteria are met: major criteria include skin hyperextensibility with atrophic scarring and generalized joint hypermobility; minimal criteria require the major criterion plus generalized joint hypermobility and/or at least three minor criteria. >90% of cEDS patients have COL5A1 or COL5A2 variants; COL1A1 variants are rare causes.clinical features as listed

    International EDS Consortium 2017.

    Vascular EDS (vEDS): Testing for vEDS (COL3A1 sequencing ± deletion/duplication) is indicated with major features such as a family history with documented COL3A1 variant, arterial rupture at a young age, unexplained sigmoid colon rupture, or uterine rupture in third trimester; testing is also indicated with combinations of minor criteria and early arterial events (<40 years). If sequencing is negative but suspicion remains, complement with CNV detection.arterial event <40 years

    International EDS Consortium 2017; CNV reflex recommended.

    Indications and testing approach for vEDS

    Testing for vEDS is indicated when clinical features meet major or suggestive minimal criteria:

    Major criteria: Presence of ANY one major criterion: family history of vEDS with documented causative COL3A1 variant; arterial rupture at a young age; spontaneous sigmoid colon perforation without diverticular disease; uterine rupture during third trimester without prior C-section; or carotid-cavernous sinus fistula without trauma.1 of 5

    Major criteria listed in policy.

    Minimal/suggestive criteria: Patients with family history of vEDS, arterial rupture/dissection <40 years, unexplained sigmoid colon rupture, or spontaneous pneumothorax in the presence of other consistent features should undergo diagnostic molecular testing for vEDS. Testing may also be considered for combinations of minor features.clinical judgment

    See policy for list of minor features.

    Testing methodology: Verification of clinical diagnosis via molecular sequencing of COL3A1 (Sanger or targeted resequencing as part of a panel including COL3A1 and COL1A1). If no variant is identified by sequencing, complement with CNV detection to identify large deletions/duplications.

    Genetic testing for isolated joint hypermobility and hypermobile Ehlers‑Danlos syndrome (hEDS) is considered investigational. Per GeneReviews and the policy background, hEDS is diagnosed by clinical evaluation and family history and the causative gene(s) are currently unknown; therefore genetic testing performed solely to evaluate isolated hypermobility or to diagnose hEDS is not appropriate or supported by this policy.

    Tests (including single‑gene sequencing/deletion‑duplication and multigene panels) are considered investigational when submitted for indications that do not meet the specific clinical criteria detailed in this policy. Examples include FBN1 testing outside the Marfan diagnostic criteria, TAAD panels for indications that do not meet the familial TAAD rules, and cEDS/vEDS testing requested for isolated hypermobility or other presentations that do not satisfy the listed major/minor or scoring thresholds.

    When a pathogenic or likely pathogenic variant is identified in a proband, only relatives who carry that same identified pathogenic variant should undergo targeted familial variant testing and then appropriate aortic imaging. This follows guideline recommendations that cascade testing and imaging be focused on relatives with the documented familial mutation to guide surveillance.

    Editorial revisions removed prior references to Hypermobile Ehlers‑Danlos syndrome from sections of the policy where genetic testing guidance applies. The policy now explicitly notes that hEDS is diagnosed clinically and that genetic testing for isolated hypermobility/hEDS is not appropriate.

    Targeted familial variant analysis (CPT 81403) and multigene panel testing (e.g., CPTs 81410, 81411) are considered investigational / not medically necessary when the applicable coverage criteria are not met. For targeted familial variant analysis, an identified pathogenic or likely pathogenic variant in a close relative is required; panels are investigational for isolated hypermobility/hEDS and for other indications not meeting the disorder‑specific criteria in this policy.

    Clinical genetic testing is not appropriate when ordered solely to evaluate for hEDS, because the gene(s) responsible for hEDS remain unknown. The policy reiterates that genetic testing should be reserved for other EDS subtypes or connective tissue disorders when the clinical criteria for those disorders are met.

    Note: the cited policy text and referenced chunks do not include explicit separate phrasing of 'not medically necessary' beyond investigational language. The policy uses investigational / investigational for other indications wording and explains denial risks where tests do not meet the defined clinical criteria.

    Tests that do not meet the clinical criteria set forth in this policy or that are restricted by plan‑level contractual limitations may be denied. Coverage decisions remain subject to the Health Plan's terms, conditions, exclusions, and administrative policies; providers should verify prior authorization requirements and document clinical findings to support medical necessity.

    Covered Indications

    Confirmation or establishment of a molecular diagnosis

    Confirmation or establishment of a molecular diagnosis for hereditary connective tissue disorders (including Marfan syndrome, Loeys-Dietz syndrome, Classic and Vascular Ehlers-Danlos) is medically necessary when specified clinical criteria or family history are met.

    Covered indications summary: Molecular testing (single-gene sequencing, deletion/duplication, or multigene panel) is indicated when the member meets disorder-specific clinical diagnostic criteria or has a close relative with a documented pathogenic variant; panels should include required minimum genes when specified (e.g., LDS and TAAD).

    See individual disorder criteria for details; CNV testing recommended when sequencing is negative but suspicion remains.

    Diagnosis confirmation of Marfan syndrome

    Diagnosis confirmation of Marfan syndrome — molecular testing is indicated when clinical diagnostic criteria are met or equivocal and can clarify diagnosis:

    Marfan diagnostic confirmation: Testing indicated in probands with aortic root enlargement (Z-score >2.0) plus ectopia lentis, or aortic root enlargement plus multiple systemic features, or in equivocal cases where clinical criteria are insufficient; family history alters thresholds per ACMG guidance.

    Coding

    Comprehensive Connective Tissue Disorders Multigene PanelCPTCovered
    81410Comprehensive connective tissue disorders multigene panel (CPT cited in policy)
    81411Comprehensive connective tissue disorders multigene panel (CPT cited in policy)
    Known Familial Variant AnalysisCPTCovered
    81403Targeted mutation analysis for a known familial variant
    Marfan syndrome - FBN1 testingCPTCovered
    81408FBN1 sequencing (used for Marfan syndrome)
    81479Unlisted molecular pathology procedure (used with FBN1 deletion/duplication in policy)
    Loeys-Dietz Syndrome Multigene PanelCPTCovered
    81405Loeys-Dietz syndrome multigene panel (CPT cited in policy)
    Other Covered Connective Tissue Disorder CodesCPT
    81400Other covered connective tissue disorder CPT range referenced
    81406CPT code referenced in TAAD/Ehlers-Danlos panel group
    Common ICD Codes referencedICD-10
    I71.00-I71.9Thoracic aortic aneurysm and dissection ICD-10 range referenced
    Q79.63ICD-10 code for vascular Ehlers-Danlos (example shown)
    M35.7ICD-10 code referenced in panels
    Referenced genetic testing CPT/PLA codesCPT
    81408Targeted sequencing; multiple genes or single gene as listed in document
    81479Unlisted molecular pathology procedure (used for deletion/duplication analysis referenced)
    81405Targeted sequencing panel (as referenced for multigene panels)
    81406Targeted sequence analysis (panel) variant
    81410Targeted sequencing, large panels
    81411Targeted sequencing, large panels variant
    81400Molecular pathology procedure, specific codes listed for other connective tissue disorders
    81401Molecular pathology procedure
    81402Molecular pathology procedure
    81403Molecular pathology procedure
    1–10 of 12
    1/2
    Previously referenced/removed CPT codesCPT
    81411Previously referenced multigene panel CPT (removed from Other Covered Connective Tissue Disorders per revision notes)
    81410Previously referenced multigene panel CPT (removed from Other Covered Connective Tissue Disorders per revision notes)
    Marfan aortic root enlargement — Z-score threshold
    ThresholdAortic root enlargement defined as Z-score >= 2.0 (used as primary aortic criterion for Marfan testing)
    ContextUsed as part of FBN1 testing criteria when member has aortic root enlargement or dissection plus ectopia lentis or systemic score >=7
    Coding relevanceZ-score >=2 triggers consideration of FBN1 sequencing and/or deletion/duplication analysis (CPT 81408, 81479)
    Aortic root enlargement definition — Z-score thresholds
    Definition

    Provider Actions

    Billing Rule

    Verify CPT and registered test on Concert Genetics

    Use the CPT/PLA code that corresponds to the exact test performed and confirm the laboratory test listing on the Concert Genetics platform before submitting claims.

    • Examples of referenced CPT codes include 81403, 81405, 81408, 81410, 81411, 81479.
    • If a panel is performed, the appropriate panel code must be used and providers should confirm registered tests on the Concert Genetics platform.
    Prior Authorization

    Prior authorization requires clinical criteria documentation

    Genetic sequencing and multigene panel tests listed in this policy require documentation that the member meets the policy's clinical criteria for the requested test to be considered medically necessary.

    Eligibility Requirements

    Eligibility for testing is based on disorder‑specific clinical criteria or a qualifying family history. For familial variant testing, a close relative must have a documented pathogenic or likely pathogenic variant. For single‑gene or panel testing, eligibility requires meeting the clinical thresholds described for each disorder (for example, aortic root enlargement Z‑score ≥2.0 for Marfan considerations, or major/minimal criteria for vEDS) and supporting clinical documentation.

    Close relatives (first‑, second‑, or third‑degree) and documented family diagnoses modify eligibility. A family history of a defined disorder can alter diagnostic thresholds (e.g., Marfan criteria) and is a recognized indication for targeted testing when a pathogenic variant is known in the proband.

    Clinical and family‑history elements that influence eligibility include: documented aortic disease or aortic root enlargement (Z‑score criteria), characteristic systemic or facial features for LDS, and major or multiple minor criteria for vEDS. The policy requires clinical documentation of these findings to support medical necessity.

    Clinical thresholds must be clearly documented. For Marfan‑related testing, an aortic root Z‑score ≥ 2.0 (or dissection) plus ectopia lentis or sufficient systemic features (systemic score ≥ 7) meets the policy threshold. Documentation should include measured aortic dimensions, scoring details, and relevant clinical findings.

    Some eligibility nodes specify minimum gene content for panels. For example, TAAD/familial aortopathy panels must include at least ACTA2, FBN1, MYH11, TGFBR1, TGFBR2, and LDS panels must include at minimum SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, TGFBR2 to satisfy policy requirements.

    Additional eligibility notes for vEDS include that testing is indicated for arterial rupture/dissection at a young age (<40 years), unexplained sigmoid colon perforation, uterine rupture in the third trimester without prior C‑section, carotid‑cavernous fistula without trauma, or a close relative with clinical vEDS. Combinations of minor criteria may also justify testing.

    Not Covered

    Genetic testing for isolated hypermobility and hEDS is investigational and therefore not covered. The policy reiterates that hEDS is a clinical diagnosis and lacks a known genetic basis, which makes molecular testing for isolated hypermobility unsupported by current evidence.

    Because the gene(s) for hEDS have not been identified, clinical genetic testing to evaluate suspected hEDS is not appropriate and is not considered a valid indication for molecular testing under this policy.

    The referenced policy sections do not enumerate explicit exclusions of named tests beyond the investigational language; instead, the policy states that panel testing or single‑gene testing is investigational when requested outside the defined clinical criteria or family‑history triggers.

    Per revision history, references to 'Comprehensive Ehlers‑Danlos Syndrome Multigene Panels' were removed from the vascular EDS section and related panel coding entries were updated; this change is reflected in the policy’s operational revisions.

    Background

    Hereditary connective tissue disorders affect multiple organ systems and commonly involve joint hypermobility and cardiovascular manifestations such as thoracic aortic aneurysms and dissections. Accurate molecular diagnosis can alter clinical management — including aortic surveillance, timing of surgical repair, pharmacologic therapy, and multisystem surveillance — and is therefore used selectively when clinical criteria or family history indicate a high pretest probability.

    Definitions

    hypermobility Ehlers-Danlos syndrome (hEDS)
    DefinitionHypermobility Ehlers-Danlos syndrome (hEDS) is diagnosed entirely by clinical evaluation and family history; causative gene(s) are currently unknown
    Testing implicationGenetic testing for isolated hEDS is not appropriate because genes are unknown
    Clinical emphasisDiagnosis relies on clinical criteria per GeneReviews; genetic evaluation addresses other EDS subtypes
    Close relative — degree definitions
    DefinitionClose relative includes first-, second-, and third-degree blood relatives
    First-degreeParents, siblings, children

    Provider Resources & Actions

    Documentation Required

    Document familial testing strategy; counseling not explicitly mandated

    The policy emphasizes familial testing strategies and cascade testing but does not explicitly mandate pre- or post-test genetic counseling; document counseling when performed and follow guideline recommendations for cascade testing.

    • Policy background supports testing an affected family member first to identify a familial pathogenic variant.
    • Record whether genetic counseling was provided even though the policy does not explicitly require it.
    Note

    Recommend counseling and targeted testing for first-degree relatives

    When a pathogenic variant is identified in a proband, offer and document genetic counseling and targeted testing for first-degree relatives as recommended by professional guidance.

    • ACC guidance recommends counseling and testing of first-degree relatives if a mutant gene is identified in a patient.

    Revision History

    2023-10-01revisionLatest

    Policy updated to version V1.2024 with editorial and structural changes including replacing 'coverage criteria' wording with 'criteria' throughout and updating title, overview, coding table, background, and references.

    2023-10-01material_change

    Removed references to Comprehensive Ehlers‑Danlos Syndrome multigene panels (CPT 81410, 81411) from the vEDS and other covered connective tissue disorders sections and removed those CPT listings.

    2023-10-01
    Policy Summary
    PayerWellCare
    PolicyConcert Genetics Genetic Testing: Aortopathies and Connective Tissue Disorders V1.2024
    Policy CodePolicy Policy 1
    Change TypeOperational editsremoval and addition of panel references
    Effective DateOct 1, 2023
    Last ReviewOct 1, 2023
    Next Review DateOct 1, 2023
    Key ActionDocument clinical criteria and family history in the record and verify appropriate CPT code and registered test on the Concert Genetics platform before submitting authorization or claims.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCodingProvider ActionsEligibility RequirementsNot CoveredBackgroundDefinitionsProvider Resources & ActionsRevision History
    sequence-negative then CNV reflex

    Testing approach described in policy.

    Z-score >2.0

    GeneReviews and ACMG guidance support these indications.

    Establish or confirm Loeys-Dietz syndrome

    Establish or confirm Loeys-Dietz syndrome — testing is medically necessary when specified clinical features are present or family history supports testing; panels must include minimum genes:

    LDS panel gene requirement: Member has clinical features consistent with LDS (e.g., craniofacial features, bifid uvula/cleft palate, arterial tortuosity, aortic dilation/dissection) AND the panel includes at minimum SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, TGFBR2.

    If both aortic root enlargement and ectopia lentis are present, include or previously test FBN1.

    HTAD multigene panels

    Familial TAAD panel — testing is medically necessary when criteria below are met and panels include required genes:

    TAAD panel gene requirement: Member has aortic root enlargement or prior thoracic aneurysm/dissection, AND does not meet diagnostic criteria for another connective tissue disorder, AND there is a family history consistent with autosomal dominant inheritance, AND the panel includes at minimum ACTA2, FBN1, MYH11, TGFBR1, TGFBR2.

    GeneReviews recommends multigene panels for HTAD.

    Classic Ehlers-Danlos syndrome testing

    Classic Ehlers-Danlos syndrome testing — molecular testing is indicated when clinical criteria are met:

    cEDS testing criteria: Member has skin hyperextensibility and atrophic scarring, AND either generalized joint hypermobility OR at least three minor criteria, AND panel limited to COL5A1, COL5A2, COL1A1.

    >90% of cEDS cases have COL5A1 or COL5A2 variants.

    Testing for rarer connective tissue disorders

    Testing for other rarer connective tissue disorders is medically necessary when clinical features match the disorder-specific gene associations listed in policy:

    Other rare disorders: Member demonstrates clinical features consistent with a listed rare connective tissue disorder (examples: arthrochalasia EDS - COL1A1/COL1A2; brittle cornea syndrome - ZNF469/PRDM5; cardiac-valvular EDS - COL1A2; dermatosparaxis EDS - ADAMTS2; and others).

    See policy list for full gene-disorder relationships.

    Suspected syndromes (Marfan, LDS, HTAD, cEDS, vEDS)

    Suspected Marfan syndrome, Loeys-Dietz syndrome, HTAD, classical or vascular Ehlers-Danlos syndrome based on clinical criteria, family history, or relevant imaging:

    Suspected syndromes guidance: Multigene panels or targeted single-gene testing are recommended depending on phenotype; include required genes for specified panels. When sequencing is negative but clinical suspicion persists, reflex CNV/deletion-duplication testing is indicated.

    Aortic root Z-score >2.0, arterial tortuosity, or early arterial rupture are examples of findings that prompt testing.

    Diagnostic testing for suspected vEDS

    Diagnostic testing for suspected vEDS — testing is indicated when major criteria or minimal/suggestive clinical features are present:

    vEDS diagnostic indications: Member meets one or more major criteria for vEDS (see policy) OR meets minimal/suggestive criteria (arterial event <40 years, unexplained organ rupture, or combinations of minor features).

    Testing should confirm a causative variant in COL3A1; consider COL1A1 in rare cases; if sequencing is negative, perform CNV testing.

    Aortic root enlargement defined as Z-score ≥ 2 (standardized to age and body size)
    Age-based noteIf >20 years, enlargement defined as >2 SDs above mean; if <20 years some diagnostic guidance uses >3 SDs in family-history contexts
    InterpretationZ-score >2 corresponds to ≥95th percentile; Z-score >3 corresponds to ≥99th percentile
    Aortic root enlargement Z-score — diagnostic threshold (>2.0 and age-based notes)
    Diagnostic threshold>2.0 (aortic root Z-score >2.0 indicates enlargement at or above the 95th percentile)
    Younger patients noteA Z-score >3.0 may be used as the threshold for individuals younger than 20 years in some family-history diagnostic criteria
    Measurement standardizationAortic size must be standardized to age and body size for accurate interpretation (use referenced calculators)
    • Covered/referenced CPT/PLA codes include 81400–81411 and 81479 as applicable.
    • Provide clinical evidence as specified for the disorder (e.g., aortic Z-score, systemic score, major/minor criteria).
    Note

    Choose phenotype-consistent multigene panel with required genes

    Order a multigene panel when the member's phenotype is consistent with HTAD or other listed syndromes and ensure the panel includes the relevant genes named in the policy.

    • HTAD panels should include, at minimum, genes such as ACTA2, FBN1, MYH11, TGFBR1, and TGFBR2 (GeneReviews lists additional HTAD genes).
    • Select a panel that matches the clinical phenotype to limit irrelevant findings.
    Prior Authorization

    Confirm and adhere to plan-level prior authorization processes

    Follow the Health Plan's administrative policies — prior authorization may be required per the plan's processes and coverage decisions are subject to plan terms and procedures.

    • Confirm any plan-level prior authorization requirements before ordering.
    • Coverage is subject to terms, conditions, exclusions, and limitations of the member's coverage documents.
    Step Therapy

    Clinical-first ordering for FBN1 sequencing/CNV testing

    Use a clinical-first approach for FBN1 testing: perform clinical evaluation and apply diagnostic scoring (aortic Z-score and systemic features) and order FBN1 sequencing and/or deletion/duplication (81408, 81479) when clinical features suggest Marfan but do not meet definitive criteria.

    • Indication requires aortic root enlargement (Z-score ≥2) or dissection plus ectopia lentis or systemic score ≥7 as described in the policy.
    • Molecular testing is appropriate in equivocal cases to clarify diagnosis.
    Step Therapy

    Prefer targeted familial variant testing (81403) when family variant known

    When a familial pathogenic or likely pathogenic variant has been identified in an index case, order targeted familial variant analysis (CPT 81403) for at-risk relatives as the preferred testing strategy.

    • Targeted mutation analysis (81403) is covered only when a close relative has a known pathogenic or likely pathogenic variant.
    • Targeted familial testing is investigational and not covered for indications without a documented familial variant.
    Step Therapy

    Initial testing: targeted single-gene or panels including key EDS genes

    For suspected cEDS or vEDS, begin with targeted single-gene testing (COL5A1/COL5A2 for cEDS; COL3A1 for vEDS) or panels that include these genes as the appropriate initial strategy.

    • cEDS panels should be limited to COL5A1, COL5A2, and COL1A1 as specified.
    • vEDS testing should include COL3A1 sequencing and/or deletion/duplication analysis.
    Step Therapy

    Reflex to CNV/deletion-duplication testing after negative sequencing

    If sequencing does not identify a causative variant and clinical suspicion remains, perform reflex or complementary CNV/deletion-duplication testing to detect large deletions or duplications.

    • Complement sequencing with a CNV detection strategy when no variant is identified.
    • Document the rationale for reflex CNV testing in the medical record.
    Documentation Required

    Include documented family history for targeted familial variant requests

    Provide documented family history showing a close relative with a known pathogenic or likely pathogenic variant when requesting targeted familial mutation analysis (81403).

    • Close relative definition includes first-, second-, and third-degree blood relatives per policy notes.
    • Lack of documented familial variant will render targeted testing investigational/not covered.
    Documentation Required

    Attach clinical evidence (aortic Z-score, systemic score, disorder-specific features)

    Include clinical documentation demonstrating diagnostic features required by the policy (e.g., aortic root Z-score, systemic feature scoring for Marfan) when ordering molecular testing.

    • For Marfan, document aortic root enlargement (Z-score ≥2) and either ectopia lentis or systemic score ≥7 with listed features.
    • For LDS, TAAD, cEDS, and vEDS, provide the specific clinical features listed in the policy that support medical necessity.
    Documentation Required

    Document family history, aortic measurements, and key clinical findings

    Ensure the medical record includes family history, aortic measurements (Z-score), and presence of key clinical features (ectopia lentis, systemic score, arterial events) to support the molecular testing request.

    • Document prior imaging, measurements, and relevant physical exam findings.
    • Record family history details, including degree of relative and documented diagnoses or variants.
    Documentation Required

    Provide vEDS-specific clinical documentation (major/minor criteria and events)

    For vEDS testing, document presence of major criteria or combinations of minor criteria and family history or clinical events (e.g., arterial rupture <40 years, unexplained sigmoid colon rupture) to justify molecular testing.

    • Major criteria include family history with documented COL3A1 variant, arterial rupture <40, unexplained sigmoid colon rupture, uterine rupture in third trimester, or carotid-cavernous sinus fistula without trauma.
    • If sequencing is negative but suspicion persists, document rationale for CNV testing.
    Denial Risk

    Investigational: targeted familial testing without a known proband variant

    Do not submit targeted familial variant analysis for relatives unless a pathogenic or likely pathogenic variant has been identified in the proband; such requests are investigational and may be denied.

    • Targeted mutation analysis (81403) is covered only when a close relative has a known pathogenic or likely pathogenic variant.
    • Requests without an identified familial variant are considered investigational.
    Denial Risk

    Investigational: panels for isolated hypermobility/hEDS

    Comprehensive multigene panels are investigational for isolated hypermobility and hypermobile Ehlers-Danlos syndrome (hEDS) and for other indications not meeting the policy's specified criteria; such requests risk denial.

    • Genetic testing for isolated hEDS is not appropriate because causative genes are unknown.
    • Panel requests for indications outside listed criteria may be considered investigational.
    Denial Risk

    Investigational: FBN1 testing outside specified Marfan indications

    FBN1 sequencing and/or deletion/duplication (81408, 81479) to establish or confirm Marfan syndrome is investigational for indications outside the policy-specified Marfan criteria and may be denied.

    • Only order FBN1 testing when the member meets the clinical criteria enumerated in the policy (e.g., aortic Z-score and systemic findings).
    • Requests for other indications are considered investigational.
    Denial Risk

    Investigational: TAAD panel requests outside familial TAAD criteria

    TAAD multigene panels are investigational for indications other than the familial TAAD criteria described in the policy and may be denied if requested outside those uses.

    • Familial TAAD panels must meet criteria including aortic disease, exclusion of other disorders, compatible family history, and minimum gene content.
    • Panels for other indications are considered investigational.
    Denial Risk

    Investigational: cEDS and COL3A1 testing for non-listed indications

    Classic EDS (cEDS) and COL3A1 (vEDS) testing are investigational for indications outside the policy-listed criteria, including isolated hypermobility/hEDS; such requests risk denial.

    • cEDS panels are limited to COL5A1, COL5A2, and COL1A1 and investigational for other uses.
    • vEDS testing (COL3A1) is investigational for indications outside the listed major/minor criteria.
    Denial Risk

    Testing cascade requirement: proband variant must be identified for targeted relative testing

    If a pathogenic variant is not identified in the index case, targeted testing of relatives may be precluded; only relatives with the identified pathogenic variant in the proband should undergo targeted testing and subsequent imaging.

    • Documented identification of a proband variant is required to trigger targeted cascade testing and imaging for relatives.
    • Absence of a proband variant may render targeted familial testing inappropriate.
    Denial Risk

    Denial risk for tests not meeting policy or plan terms

    Coverage decisions are subject to the member's plan terms and administrative policies; tests that do not meet the policy's medical necessity criteria or plan contractual limitations may be denied.

    • Confirm benefits and prior authorization requirements with the member's Health Plan before testing.
    • Maintain complete documentation to support medical necessity.

    Procedural eligibility requires using the correct CPT/PLA code for the selected test and may require prior authorization per the Health Plan’s processes. Providers should verify the exact test and code on authorized platforms before claims submission.

    Eligibility for specific subgroups (for example, first‑degree relatives of an index case with a known pathogenic variant) is distinct: when a familial pathogenic variant is identified, targeted testing of at‑risk relatives is the preferred, efficient strategy and is covered if the index variant is documented.

    Second-degree
    Grandparents, aunts/uncles, nieces/nephews, grandchildren, half-siblings
    Third-degreeGreat-grandparents, great aunts/uncles, great-grandchildren, first cousins
    Aortic root enlargement (Z-score >2.0) — standardized measurement
    Standardized measurementAortic root measurement standardized to age and body size where Z-score >2.0 indicates enlargement (≥95th percentile)
    Clinical useZ-score >2.0 is used as a diagnostic criterion for Marfan syndrome and related disorders
    Percentile interpretationZ-score >2.0 ≈ ≥95th percentile; Z-score >3.0 ≈ ≥99th percentile
    Loeys-Dietz syndrome genetic confirmation — gene plus aortic findings
    Genetic confirmation criteriaLoeys-Dietz syndrome is established with a heterozygous pathogenic/likely pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 PLUS either aortic root enlargement (Z-score >2.0) or compatible systemic features
    Aortic findingAortic root enlargement defined as Z-score >2.0 or type A dissection
    Systemic featuresIncludes characteristic craniofacial, skeletal, cutaneous, and vascular manifestations (emphasis on arterial tortuosity and aneurysms/dissections)
    Vascular Ehlers-Danlos syndrome (vEDS) — COL3A1
    Primary causeVascular Ehlers-Danlos syndrome (vEDS) is most commonly caused by heterozygous pathogenic variants in COL3A1
    Clinical consequencesCOL3A1 variants lead to arterial rupture, organ rupture, and tissue fragility
    Testing approachMolecular screening by Sanger sequencing or targeted resequencing including COL3A1 (and COL1A1 in rare cases); if negative, complement with CNV detection
  1. Only relatives with the identified pathogenic variant should undergo aortic imaging.
  2. Documentation Required

    Document implications of results and provide counseling as appropriate

    Consider and document the implications of genetic test results for treatment, natural history, and recurrence risk; the policy implies genetic counseling is part of cascade testing and management.

    • Use test results to guide aortic surveillance, surgical decisions, and family risk assessment.
    • Document counseling about recurrence risk and management implications when testing is performed.
    Note

    Order tests based on clinical evaluation and family strategy; document indications

    Order testing guided by clinical evaluation and family testing strategies; ensure the ordering provider documents clinical indications and family history per the policy's requirements.

    • Policy does not restrict which provider may order testing; providers must exercise professional judgment and document indications.
    • Include disorder-specific clinical findings and family history in the order to support medical necessity.
    Documentation Required

    Document recommendations and actions for first-degree relatives after proband variant identification

    When recommending testing or counseling for first-degree relatives after identification of a pathogenic variant, the ordering provider should document the test rationale and referral/counseling actions in the medical record.

    • Document that first-degree relatives were offered testing/counseling and any follow-up imaging plans.
    • Ensure records identify the proband variant and degree of relatedness for cascade testing.
    Note

    Ordering responsibility: professional judgment expected (no provider restriction specified)

    The policy does not specify which clinicians may order tests; providers are expected to use professional medical judgment and be responsible for appropriate ordering and documentation.

    • Ensure documentation supports medical necessity regardless of ordering clinician specialty.
    • Follow plan prior authorization and ordering procedures as applicable.
    material_change

    Added alignment to GeneReviews content and updated gene lists to include genes associated with heritable thoracic aortic disease (HTAD), and added GeneReviews citations (e.g., FBN1‑Related Marfan Syndrome) to background and rationale.